Journal
FUTURE ONCOLOGY
Volume 12, Issue 4, Pages 565-574Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.15.320
Keywords
ataxin-3; CYLD; deubiquitination; SUMOylation; USP25; USP28; USP39
Categories
Funding
- Swedish Cancer Foundation
- European Research Council (ERC) under European Union [260460]
- Ministerio de Ciencia e Innovacion [BFU2010-15656, SAF2013-49069-C2-1-R]
- Generalitat de Catalunya [SGR2014-0932]
- European Research Council (ERC) [260460] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Deubiquitinating enzymes (DUBs) are specialized proteins that can recognize ubiquitinated proteins, and after direct interaction, deconjugate monomeric or polymeric ubiquitin chains, thus changing the fate of the substrates. This process is instrumental in mediating or changing downstream signaling pathways. Beside mutations and alterations in their expression levels, the activity and stability of deubiquitinating enzymes is vital for their function. SUMOylations consist of the conjugation of the small peptide SUMO to protein substrates which is very similar to ubiquitination in the mechanistic and machinery required. In this review, we will focus on how SUMOylation can regulate DUB enzymatic activity, stability or DUB interaction with partners and substrates, in cancer. Furthermore, we will discuss the impact of these recent findings in the identification of new potential tools for efficient anticancer treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available